Enhanced Ivermectin and Mebendazole Framework: A 16-Week Metabolic Approach Targeting Mitochondrial Dysfunction and Cancer Stem Cells in Resistant and Metastatic Cancers
The 7-Layer Metabolic Therapy Cancer Protocol
Abstract
If cancer were driven by a single pathway, one drug would cure it. But as outlined in The 10 Hallmarks of Metabolic Cancer, cancer cells are:
Metabolically flexible
Highly adaptive
Able to evade both drugs and the immune system
This is why most treatments fail long-term. The solution? Layered intervention.
This review proposes a conceptual seven-layer metabolic intervention framework designed to target multiple metabolic vulnerabilities simultaneously. The framework integrates and ties all the components of metabolic management of cancer including dietary metabolic modulation, standard conventional treatments (chemotherapy, immunotherapy, surgery and radiotherapy), repurposed pharmacological agents such as ivermectin and mebendazole, mitochondrial targeting strategies including metformin, anti-inflammatory nutraceuticals, cancer stem cell targeting, immune metabolic support, and lifestyle interventions.
It is important to emphasize that while each component is important, the different strategies act together synergistically to achieve the best outcome. This review provides an overview of the topic.
Although several components of this framework are supported by preclinical and early clinical evidence, many remain investigational. Controlled clinical trials are necessary to determine safety, efficacy, and optimal integration with standard oncology care.
Keywords: Mitochondrial-Stem Cell Connection, Cancer Stem Cells, Orthomolecular Medicine, Ketogenic Diet, Insulin Resistance, Repurposed Drugs.
Introduction
Despite advances in oncology, conventional treatments grounded in the somatic mutation theory (SMT)—which emphasizes genetic alterations as the main oncogenic drivers—often fail to eradicate cancer stem cells, leading to tumor relapse and metastasis. The metabolic theory of cancer, pioneered by Otto Warburg, highlights mitochondrial dysfunction and a shift to aerobic glycolysis as fundamental features of cancer metabolism.
Building on this, the Mitochondrial-Stem Cell Connection (MSCC) theory postulates that impaired oxidative phosphorylation (OxPhos) in stem cells causes reliance on fermentative metabolism (glycolysis and glutaminolysis), which drives CSC formation, tumorigenesis, metastasis, and therapy resistance.
In a 2024 published study, a new concept was introduced the mitochondrial-stem cell connection (MSCC) (Martinez, et al., 2024). This concept combines the cancer stem cell theory and the metabolic theory.
Orthomolecular medicine, which optimizes nutrient and metabolic status, represents a viable, non-toxic means to target MSCC.
The original protocol by Baghli et al (1) combined high-dose vitamins, repurposed drugs like ivermectin, and ketogenic diets to enhance OxPhos and inhibit CSCs. However, it lacked phasing, personalization, and integration of emerging agents. Recent studies (2024-2025) validate mitochondrial targeting, with agents like atovaquone inhibiting complex III (2) and berberine activating AMPK to suppress CSC stemness (3). Intermittent fasting amplifies autophagy in CSCs (4), while hyperbaric oxygen therapy (HBOT) boosts mitochondrial biogenesis (5).
This article proposes an improved hybrid protocol, extending the original 12-week regimen to 16 weeks with phases for induction, consolidation, and maintenance. It incorporates evidence-based additions and safety enhancements, aiming to improve efficacy in resistant cancers.
Protocol Overview
The enhanced protocol is designed as a high level guide and framework adaptable to cancer grade and individual patient response.
After reviewing the literature on various therapies capable of targeting cancer metabolism and cancer stem cells (CSCs), we selected, based on pre-clinical studies and case reports, several drugs, and additional therapies that have demonstrated an ability to target cancer metabolism, CSCs and metastasis.
From this combination, we developed a seven-layer metabolic intervention framework integrating diet, repurposed pharmacological agents, mitochondrial inhibitors, nutraceuticals, and lifestyle interventions to target tumor metabolism from multiple angles.
Phased Implementation
Induction Phase (Weeks 1–4): High-intensity treatment.
Consolidation Phase (Weeks 5–12): Metabolic stabilization and response-based dose adjustments.
Maintenance Phase (Weeks 13–16+): Lower doses for relapse prevention.
Layer 1: Metabolic Dietary Interventions
Dietary interventions aimed at modifying systemic metabolism have been investigated as potential adjunctive therapies in oncology.
Diets emphasizing plant-based foods, high fiber, and reduced processed sugar may influence metabolic pathways linked to cancer progression. Observational studies suggest potential benefits in prevention and survivorship, although randomized trials are limited. (Read More)
One commonly studied approach is the ketogenic diet, which is characterized by high fat intake, moderate protein consumption, and significant carbohydrate restriction. By lowering circulating glucose and insulin levels, ketogenic diets may alter the metabolic environment in which tumors grow.
Some studies suggest that ketogenic diets may reduce tumor growth in preclinical models while improving metabolic parameters in patients. Additionally, intermittent fasting and fasting-mimicking diets have been explored as strategies to increase tumor sensitivity to chemotherapy while protecting normal cells through stress-response pathways.
Potential risk: Chronic extreme fasting can compromise immune surveillance.
Although clinical evidence remains limited, these interventions may represent a promising area of metabolic oncology research.
Layer 2: Tumor-directed therapy
Surgery (when feasible)
Chemotherapy
Radiation therapy
Immunotherapy
Targeted Therapy
Layer 3: Repurposed Drugs
Drug repurposing has emerged as a cost-effective strategy for identifying novel cancer therapies. Several anti-parasitic agents have demonstrated anticancer activity in preclinical studies.
Ivermectin
Ivermectin is widely used as an antiparasitic medication. Experimental studies suggest that ivermectin may exert anticancer effects through multiple mechanisms, including inhibition of the PI3K/AKT/mTOR signaling pathway, disruption of mitochondrial function, induction of oxidative stress, and modulation of autophagy.
These effects have been observed in several tumor types, including breast, ovarian, and colorectal cancers.
Mebendazole
Mebendazole is a benzimidazole compound that disrupts microtubule polymerization. Because microtubules are essential for mitosis, their disruption can induce cell cycle arrest and apoptosis in rapidly dividing tumor cells.
Additional studies suggest that mebendazole may inhibit angiogenesis and suppress multidrug resistance proteins.
Fenbendazole
Fenbendazole is a structurally related benzimidazole drug primarily used in veterinary medicine. Preclinical research suggests potential anticancer mechanisms similar to those of mebendazole, including microtubule disruption and metabolic interference. However, clinical evidence remains limited.
Niclosamide
Niclosamide: 650 mg/day for 6 months (Familial adenomatous polyposis) (NCT04296851) and 2,000 mg/day (until progression or unacceptable side effects) for metastatic colorectal cancer (NIKOLO 2018).
Atovaquone
Atovaquone: Dosage: 250-500 mg/day orally. Schedule: All phases; monitor liver function. Rationale/Improvements: Targets complex III, eradicating CSCs in hypoxic environments; 2024-2025 studies show synergy with immunotherapy. (Nature 2024)
Combination
A 2026 systematic review of “Triple Combination of Ivermectin, Fenbendazole, and Mebendazole in Cancer” demonstrated complementary mechanisms of action across all three agents. 13 publicly reported cases suggest temporal associations with tumor shrinkage or biomarker improvements.
Quadruple combination of ivermectin, mebendazole, fenbendazole and niclosamide for tongue cancer: A case report by Dr William Makis (X.com 2026)
Key Takeaway
Ivermectin and mebendazole show consistent anticancer activity in vitro and animal models, case reports but lack high-quality large human clinical trials (PubMed).
Read More: Fenbendazole, Ivermectin and Mebendazole Cancer Success Stories: 590 Case Reports Compilation (2026 Edition)
Layer 4: Nutraceuticals
Chronic inflammation contributes to tumor initiation and progression by activating signaling pathways such as NF-κB, STAT3, and HIF-1α.
Several nutraceutical compounds have been investigated for their potential anti-inflammatory and anticancer properties.
Curcumin, a polyphenol derived from turmeric, has demonstrated anti-inflammatory, antioxidant, and anti-angiogenic effects in numerous experimental studies. Omega-3 fatty acids have also been associated with reduced inflammation and improved metabolic health. In addition, vitamin D plays an important role in immune regulation and cellular differentiation.
While these compounds are not substitutes for conventional therapies, they may contribute to broader metabolic and inflammatory modulation.
Dosages
Curcumin: Dosage: 500-1000 mg orally, 2-3 times/day (preferably as liposomal or with piperine for bioavailability, up to 3000 mg/day total). Schedule: All phases; monitor liver function. Rationale/Improvements: Natural polyphenol that induces mitochondrial dysfunction and oxidative stress in CSCs, promotes mitophagy, and inhibits tumor growth; preclinical and clinical data support its role in targeting mitochondrial pathways in various cancers, with potential synergy in orthomolecular protocols .
Berberine (Alternative to Metformin): Dosage: 500 mg, 2 times/day orally. Schedule: All phases. Rationale/Improvements: Phytochemical with evidence analogous to metformin in down-regulating CSC genes. Activates AMPK, inhibiting mTOR and CSC tumorigenicity; evidence supports suppression of stemness in colorectal and breast cancers.
Oral Vitamin D3: Dosage: Titrate to 80-100 ng/mL serum (e.g., 50,000 IU/day if <30 ng/mL; 5,000 IU/day if 60-80 ng/mL), then maintain at 2,000 IU/day. Schedule: All phases; biweekly monitoring. Rationale/Improvements: Linked to reduced mitochondrial dysfunction in cancer studies; essential in protocol for serum optimization, though more supportive than direct targeting. Regulates mitochondrial respiration and inhibits CSC pathways; 2024 studies link it to reduced mitochondrial dysfunction in cancer. (1)
Vitamin K2: Dosage: 100 mcg/day. Complements Vitamin D3 to prevent calcification and support mitochondrial function. Primarily for balancing high-dose D3; indirect benefits in cancer protocols with minimal standalone CSC targeting evidence.
Layer 5: Targeting Cancer Stem Cells
Cancer stem cells (CSCs) represent a subpopulation of tumor cells capable of self-renewal, metastasis, and resistance to therapy.
Recent studies suggest that CSCs often rely on distinct metabolic pathways, including mitochondrial oxidative phosphorylation and fatty acid metabolism.
Strategies that disrupt these metabolic pathways—including mitochondrial inhibitors and microtubule-targeting drugs—may therefore help reduce tumor recurrence and metastasis.
Read More: Targeting the Mitochondrial-Stem Cell Connection in Cancer Treatment: A Hybrid Orthomolecular Protocol
Layer 6: Immune Metabolism Support and Mitochondrial Targeting
Tumor metabolism can suppress immune function within the tumor microenvironment. Elevated lactate concentrations, for example, can inhibit cytotoxic T cells and natural killer cells.
Interventions aimed at improving immune metabolism may therefore enhance antitumor immune responses. Nutrients such as vitamin C have been investigated for their potential role in supporting immune function and reducing oxidative stress.
Mitochondrial Targeting
Mitochondria play a critical role in cancer metabolism, particularly in therapy-resistant tumors and cancer stem cells.
One widely studied metabolic drug is metformin, a biguanide used in the treatment of type 2 diabetes. Metformin inhibits mitochondrial complex I, leading to decreased ATP production and activation of the AMP-activated protein kinase (AMPK) pathway.
These effects may reduce tumor growth through both metabolic and endocrine mechanisms, including decreased insulin signaling.
Layer 7: Lifestyle and Metabolic Optimization
Lifestyle factors play an important role in systemic metabolism and cancer risk.
Regular physical activity has been associated with improved mitochondrial function, reduced insulin resistance, and enhanced immune surveillance. Potential risk: Overtraining, chronic high-intensity exercise, or inadequate recovery can increase systemic inflammation.
Adequate sleep and circadian rhythm regulation also influence metabolic signaling pathways involved in cancer progression.
Stress management strategies—including meditation and behavioral interventions—may further reduce inflammatory signaling and improve overall metabolic health.
Monitoring and Personalization
Baseline assessments include liver and kidney functions, mitochondrial function (e.g., lactate levels), serum nutrients, ketone levels (targeting >2 mmol/L), and tumor markers. Weekly biomarker tracking allows dose adjustments to maximize efficacy and minimize toxicity. Integration with standard oncological care is recommended with vigilance for interactions.
Evidence and Rationale
Preclinical and clinical studies validate mitochondrial targeting agents like atovaquone and berberine, demonstrating CSC inhibition and synergy with immunotherapy.
Discussion
This enhanced hybrid protocol overcomes several limitations of earlier approaches by introducing phased dosing for improved patient adherence, reducing toxicity risks, and incorporating novel agents targeting multiple facets of mitochondrial dysfunction and Cancer Stem Cell biology. Its low-cost, multimodal design leverages accessible drugs and lifestyle interventions, offering a pragmatic adjunct for resistant and metastatic cancers.
Limitations and Considerations
Need for Clinical Trials: While preclinical and in silico data are promising, robust real-world clinical trial data in diverse patient populations are required to confirm safety, efficacy, and optimal integration with standard cancer therapies.
Complexity of Protocol: The multi-agent, multi-phase regimen demands careful medical supervision, patient adherence, and monitoring.
Potential Drug Interactions and Toxicities: Despite monitoring guidelines, combining several repurposed drugs and supplements raises risks that require clinical monitoring and further real-world evaluation.
Generalizability: Variable responses based on cancer type, stage, and individual metabolic status may affect outcomes, emphasizing the need for personalized approaches.
Conclusion
The enhanced metabolic cancer protocol represents a pioneering, well-structured, scientifically grounded enhanced orthomolecular protocol targeting the mitochondrial-stem cell connection to combat resistant and metastatic cancers.
By combining metabolic, pharmacologic, dietary, and lifestyle interventions, it proposes a promising adjunctive treatment that could overcome limitations of current genetically focused therapies. The protocol’s phased design, novel agents, and updated mechanistic rationale mark significant advances in this niche field. However, clinical trials remain essential to validate its efficacy and safety before broad clinical adoption.
Disclaimer:
Experimental/Unproven Protocol for Cancer—For Research/Discussion Only.
References
Baghli et al. (2024). Targeting the Mitochondrial-Stem Cell Connection in Cancer Treatment: A Hybrid Orthomolecular Protocol
Rodriguez-Berriguete et al. Antitumour effect of the mitochondrial complex III inhibitor Atovaquone in combination with anti-PD-L1 therapy in mouse cancer models. (Nature 2024)
Nour Ibrahim et al. Berberine Inhibits Breast Cancer Stem Cell Development and Decreases Inflammation: Involvement of miRNAs and IL-6 (Current Developments in Nutrition 2025)
Wolska et al. The Role of Intermittent Fasting in the Activation of Autophagy Processes in the Context of Cancer Diseases (2025)
Young et al. Hyperbaric oxygen increases mitochondrial biogenesis and function with oxidative stress in HL-1 cardiomyocytes (2025)
Hyperbaric Oxygen Therapy (HBOT) — A Vastly Underused Treatment Modality (OneDayMD 2025)
Integrative Naturopathic Treatment Model for Colorectal Cancer: A Retrospective Study (N=131 stage 4 colorectal cancer) (Integrative Medicine and Health 2025)
The Effect of Integrative Naturopathic Oncology Including Modulated Electrohyperthermia on Survival Outcome among Glioblastoma Multiforme Patients: A Retrospective Study (N=73 stage 4 Glioblastoma) (Integrative Cancer Therapies 2025)
Fenbendazole and Ivermectin for Lung Cancer Success Stories: 31 Case Reports Compilation (December 2025 Edition)
The magic bullet: Niclosamide (Frontiers Oncology 2022)
Drug Repurposing to Enhance Antitumor Response to PD-1/PD-L1 Immune Checkpoint Inhibitors (Cancers 2022)
Systematic Review: Triple Combination of Ivermectin, Fenbendazole, and Mebendazole in Cancer (2026)
Quadruple combination of ivermectin, mebendazole, fenbendazole and niclosamide for tongue cancer: A case report by Dr William Makis (X.com 2026)
27 Best Alternative Cancer Treatments 2026: Proven Interventions (Cancer Advisor)
The Wellness Company’s Ivermectin and Mebendazole
Ivermectin and mebendazole, both approved for human use, are now available in the U.S.
Researched and approved by Dr. Peter McCullough.
Prescribed by licensed medical professionals
Compounded and dispensed by a licensed US-based pharmacy
Approved for human use
Where to buy Ivermectin and Mebendazole Formula: Available on The Wellness Company’s website. Here is the link: Ivermectin and Mebendazole.
Need to find an alternative to IV Vitamin C. Prices here locally in California are $250 per session, 3X per week, at 16 weeks is about $12,000, which is prohibitive for most people. About the same price, slightly lower, for HBOT. Need to find other ways of offering these benefits
Wow. This is amazing.